CHSU Discovery

Abstract

Age-related macular degeneration (AMD) is the fourth leading cause of blindness in older adults and is estimated to affect 8.7% of the global population. The neovascular, or exudative (“wet”), form of the disease currently requires long-term treatment with intravitreal anti–vascular endothelial growth factor (VEGF) pharmacotherapy, resulting in a high treatment and office visit burden experienced by patients and their caregivers. Recently there have been several promising updates from clinical trial programs exploring the role of various gene therapies in nAMD.